BD Drives the Future of Immunology Research with Expanded Offerings for Simultaneous RNA and Protein Expression Analysis

FRANKLIN LAKES, N.J., July 26, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial release of the BD® AbSeq assay to analyze protein expression at the single-cell level using high-throughput sequencing. The assay brings together high-quality antibodies from the BD Pharmingen™ portfolio with oligonucleotides,... Read more

Gyros Protein Technologies and Cygnus Technologies sign licensing and supply agreement

Uppsala, Sweden and Southport, N.C., July 10, 2018: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, and Cygnus Technologies, the leading assay and services provider for the detection and characterization of impurities in biopharmaceuticals, today announced they have signed a licensing and supply agreement. Under the... Read more

Labcyte to Support GP-write Project Under New Agreement with Center of Excellence for Engineering Biology

Researchers Will Receive Preferred Pricing and Early Access to New Technologies for Understanding the Blueprint for Life Provided by the Human Genome Project (HGP-read) July 17, 2018 SAN JOSE, California Labcyte Inc. today announced an agreement with the Center for Excellence in Engineering Biology (CEEB), an independent nonprofit that is managing initial planning and coordination... Read more

Swift Biosciences Launches Swift 2S Turbo Library Kit, Accelerating Whole Genome, Exome and Large Gene Studies with One Universal Approach

(ANN ARBOR, Mich. – July 18, 2018) Swift Biosciences, a leading provider of innovative library prep solutions for next-generation sequencing (NGS), today announced early access to its Swift 2S Turbo Library Kit. These new kits offer a fast, robust enzymatic fragmentation prep and flexible adapter options to produce high-quality libraries for production-scale sequencing. With an automation... Read more

Takara Bio strengthens its IP position on single cell RNA-seq

MOUNTAIN VIEW, Calif., July 18, 2018 /PRNewswire/ — Takara Bio USA, Inc., (TBUSA, formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., is proud to announce that patent JP6336080B—covering the Smart-seq2 method, developed by Rickard Sandberg and exclusively licensed to TBUSA by the Ludwig Institute—has been awarded by the Japan Patent Office. Additional patents regarding the Smart-seq2 technology... Read more

DNA-Based Pathogen Testing Company PathogenDx Raises $3.4 Million in Convertible Note Round

TUCSON, Ariz., July 17, 2018 /PRNewswire/ — PathogenDx Corporation, the innovative provider of DNA-based pathogen testing technology for the cannabis, botanical, food and agriculture industries, announced today the successful completion of a $3.4 million capital raise, completing the company’s convertible note round. The PathogenDx capital raise was co-led by Altitude Investment Management and The Panther Opportunity Fund. Other key funders include CanopyVentures,... Read more

QIAGEN partners with U.K. to expand biomarker research in Manchester

Manchester, United Kingdom, and Hilden, Germany, July 11, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with multiple organizations to support creating a global genomics campus in Manchester, U.K., for innovation, life sciences, translational science and molecular diagnostics. QIAGEN is working with Health Innovation Manchester, the partnership which brings... Read more

Bio-Techne Scales Antibody Validation Initiative Using CRISPR Gene Editing Technology Across a Broad Spectrum of Targets

 Download as PDF JULY 10, 2018 Knockout Validation of Antibodies Confirms Specificity and Ensures Reproducible Results MINNEAPOLIS, July 10, 2018 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH), a family of brands with a unique and leading portfolio of antibody-based reagents for life science and clinical research, has been validating an extensive and growing number of antibodies using... Read more

Agena Announces MassARRAY® Commercial Partnership Agreement With Dian For China Clinical Laboratory Market

San Diego, CA, July 10, 2018 – Agena Bioscience announced today that it has entered into a commercial partnership agreement with Zhejiang Dian Diagnostics Co., Ltd (“Dian”), one of China’s largest independent medical laboratories provider. The strategic agreement will enable Dian to promote and broadly commercialize Agena’s MassARRAY® System and DNA testing applications and products throughout... Read more

Pacific Biosciences Selected for NSF Project to Rapidly Sequence Maize Pangenome

MENLO PARK, Calif., July 10, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that a multi-institutional consortium of maize researchers is using the Sequel® System to create a 26-line pangenome reference collection. Led by faculty investigator R. Kelly Dawe, Distinguished... Read more